ApoB counts particles; LDL only weighs their cargo. When both are tracked against future heart attacks in the same people, ApoB wins every time: nine head-to-head studies, ApoB the better predictor in all nine 1. In nearly 400,000 people, the LDL signal all but vanished once ApoB was accounted for 2.
Lp(a) is set by one gene and barely moves after that. The higher it is, the higher your coronary risk, in a straight line 3. People who inherit the high-Lp(a) gene get more heart attacks in exact proportion, the cleanest causal evidence biology offers 4. It also roughly doubles the odds of a calcified, leaky aortic valve 5. Diet, exercise, and statins don't touch it 6.
This is why "normal" labs still end in a parking-lot heart attack. Over a billion people carry Lp(a) above the risk threshold and mostly find out only after the first event 6. Up to a third of people on a statin hit a green-zone LDL while their ApoB stays over target: same arterial damage, congratulated for it 7.
At your next blood draw, add two tests to the usual panel. No fasting, both routine at any major lab.
Lp(a) almost never needs a retest. ApoB shifts with treatment, so re-check it when you start or change a lipid drug.
The result changes a decade of your life. For four readers in five it's reassurance for life: Lp(a) under the line, one less hidden number. For the fifth, a high result before forty pulls every downstream move a decade earlier: tighter ApoB targets, blood pressure watched sooner, family tested, first in line when the new Lp(a)-lowering drugs clear their trials 8. What it buys is the heart attack that doesn't happen in your fifties.
The fine print — when to skip it, and what people get wrong
- "My LDL is fine, so I'm fine." About a quarter of adults have a normal LDL and an elevated ApoB, usually with belly weight, high triglycerides, or pre-diabetes 1.
- "I'll lower
Lp(a)with diet and exercise." You can't; only PCSK9 inhibitors nudge it, about 25% 9. - "The 50 mg/dL threshold fits everyone." It came from White European data; treat a borderline result more seriously if you're Black or South Asian 10.
- The old assay. Mass-based mg/dL tests misread by particle size; ask for the
nmol/Lmonoclonal assay 11. - Tested while sick. Infection shifts both markers; if a result looks off, retest a month later.
None. Both run on the same draw as any other lab; only an acute illness skews them temporarily.
- 1Sniderman AD, Thanassoulis G, Glavinovic T, et al. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. link
- 2Marston NA, Giugliano RP, Melloni GEM, et al. (2022). Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiology. link
- 3Erqou S, Kaptoge S, Perry PL, et al. (Emerging Risk Factors Collaboration) (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. link
- 4Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009). Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. link
- 5Thanassoulis G, Campbell CY, Owens DS, et al. (2013). Genetic associations with valvular calcification and aortic stenosis. New England Journal of Medicine. link
- 6Kronenberg F, Mora S, Stroes ESG, et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. link
- 7Wilkinson MJ, Lepor NE, Michos ED, et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. link
- 8O'Donoghue ML, Rosenson RS, Gencer B, et al. (2022). Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease (OCEAN(a)-DOSE). New England Journal of Medicine. link
- 9O'Donoghue ML, Fazio S, Giugliano RP, et al. (2019). Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. link
- 10Paré G, Çaku A, McQueen M, et al. (2019). Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. link
- 11Marcovina SM, Albers JJ (2022). Lipoprotein(a) measurement issues: are we making a mountain out of a molehill? Atherosclerosis. link
დაკავშირებული სახელმძღვანელოში (11)
- — Very high ApoB running in a family points toward familial hypercholesterolemia — worth chasing down.
- — High ApoB or Lp(a) damages arteries everywhere, the aorta included. If you've ever smoked, still get the one-time aneurysm scan at 65.
- — These two are the core of the broader advanced cardiac panel.
- — ε4 also raises cardiovascular risk through cholesterol, and carriers should treat to tighter targets — so know your ApoB and Lp(a).
- — A zero calcium score can still miss plaque in high-Lp(a) people — pair the scan with the lipid markers.
- — ApoB and Lp(a) catch hidden risk a basic cholesterol panel misses — useful for the under-recognised female case.
- — A normal-looking cholesterol panel can lull you — apoB is how you read past the reassuring number.
- — ApoB is the particle count these drugs drive down, and Lp(a) is the one only PCSK9 inhibitors really touch.
- — ApoB is the better number for judging whether you actually need to lower cholesterol before you reach for any statin, supplement or not.
- — ApoB and the lipid panel are what actually tell you whether your fat choices are landing where it counts.
- — The clot that blacked out your eye broke off a plaque. ApoB and Lp(a) are the lipid numbers driving that plaque.
ApoB and Lipoprotein(a)
ApoB ~$10-30, Lp(a) ~$25-80 at major US reference labs at list price; often covered by insurance with relevant diagnosis. Lp(a) is once-in-lifetime, so the cumulative cost falls well under $50 over the reader's lifetime.
A single venous blood draw added to a standard lipid panel, no fasting required for either marker. The effort is bringing up the test name with the ordering clinician — minutes, not a lifestyle change.
Biomarker-risk relationship is Cochrane-grade for both markers. ApoB: Marston et al. 2022 (UK Biobank n=389,529 plus FOURIER and IMPROVE-IT); Sniderman 2019 narrative review of nine head-to-head cohort comparisons; ESC/EAS 2019 and NLA 2024 expert consensus. Lp(a): ERFC 2009 meta-analysis of 36 studies (n=126,634); Kamstrup 2009 Copenhagen genetic Mendelian-randomization; Burgess 2018 multi-variant MR; EAS 2022 consensus statement. Both endorsed by ESC/EAS guidelines.
Identifies the ~20% of adults with elevated Lp(a) — a causal driver of ASCVD and calcific aortic stenosis with lifetime risk equivalent to heterozygous familial hypercholesterolemia at the highest decile (Kronenberg 2022, Mach 2020, Thanassoulis 2013). Also resolves ApoB/LDL-C discordance, common in metabolic syndrome and diabetes, where ApoB tracks MI risk independently of LDL-C content (Marston 2022, Sniderman 2019, Wilkinson 2024). The measurement itself does not extend life; the action it triggers (earlier and more aggressive lipid-lowering, family cascade testing) does. Scored as a large but not dominant longevity effect, since the test only delivers its benefit through downstream therapies that are scored separately.